甲状腺乳头状癌患者TCAB1、lncRNA DLEU2表达与临床病理参数及预后的相关性

doi:10.3760/cma.j.issn.1007-1245.2024.19.027

摘要/Abstract

摘要：

目的　探讨甲状腺乳头状癌（PTC）患者组织中端粒酶卡哈尔体蛋白1（TCAB1）、长链非编码RNA DLEU2（lncRNA DLEU2）表达与临床病理参数及预后的相关性。方法　前瞻性选取陕西省肿瘤医院2018年1月至2021年1月收治的80例PTC患者。其中，男35例，女45例；年龄38～78（54.65±4.75）岁。取所有受检者术后癌组织及癌旁正常组织进行免疫组化检验。采用免疫组织化学染色方法检测癌组织及癌旁正常组织TCAB1、lncRNA DLEU2的表达水平，分析不同病理参数患者TCAB1、lncRNA DLEU2表达情况，采用Spearman相关性分析TCAB1、lncRNA DLEU2与PTC临床病理参数的相关性。对所有患者进行3年随访，将发生新的转移灶、复发灶及死亡的患者分为预后不良组（20例），其余患者为预后良好组（60例）。分析两组患者TCAB1、lncRNA DLEU2表达水平，采用logistic回归分析模型分析TCAB1、lncRNA DLEU2对PTC的预后预测价值。行t检验、χ²检验。结果　癌组织lncRNA DLEU2相对表达量与TCAB1阳性率均高于癌旁组织［（1.44±0.27）比（0.75±0.12），72.78%（49/80）比14.79%（22/80）］，差异均有统计学意义（t=16.14，χ²=18.46，均P<0.05）；不同TNM分期、淋巴结转移情况患者lncRNA DLEU2相对表达量、TCAB1阳性率对比差异均有统计学意义（均P<0.05）；Spearman相关分析结果显示TCAB1与临床分期、淋巴结转移呈正相关（r=0.428，0.353；均P<0.05），lncRNA DLEU2与临床分期、淋巴结转移呈正相关（r=0.430，0.401；均P<0.05）；预后不良组lncRNA DLEU2相对表达量与TCAB1阳性率均高于预后良好组［（1.68±0.25）比（1.25±0.13），85.00%（17/20）比53.33%（32/60）］，差异均有统计学意义（t=8.48，χ²=6.34，均P<0.05）；TCAB1阳性表达、lncRNA DLEU2相对表达量增加为PTC预后独立影响因素（OR=2.791，95%CI 1.457～5.745；OR=2.146，95%CI 1.525～6.795），均P<0.001）。结论　PTC患者TCAB1、lncRNA DLEU2表达水平与PTC的发生与发展密切相关，可通过检测TCAB1、lncRNA DLEU2表达来预测患者预后情况。

关键词:

甲状腺癌, 甲状腺乳头状癌, 端粒酶卡哈尔体蛋白1, 长链非编码RNA, 病理参数, 预后

Abstract:

Objective　To investigate the correlation of the expression levels of telomerase Cahalin protein 1 (TCAB1) and long chain non-coding RNA (lncRNA) DLEU2 in the tissues of patients with papillary thyroid carcinoma with their clinical pathological parameters and prognosis. Methods　Eighty patients with PTC treated at Shaanxi Provincial Tumor Hospital from January 2018 to January 2021 were selected, including 35 males and 45 females who were 38-78 (54.65±4.75) years old. The patients' cancer tissue and adjacent tissue were collected for immunohistochemical examination. The immunohistochemical staining was used to detect the expression levels of TCAB1 and lncRNA DLEU2 in the cancer tissue and adjacent tissue. The expression levels of TCAB1 and lncRNA DLEU2 in the patients with different pathological parameters were analyzed. Spearman correlation analysis was used to analyze the correlation of TCAB1 and lncRNA DLEU2 with the clinical pathological parameters of PTC. All the patients were followed up for 3 years, and were divided into 2 subgroups based on their prognosis. Twenty patients with new metastases and recurrent lesions and who died were set as a poor prognosis group. The remaining 60 patients were set as a good prognosis group. The expression levels of TCAB1 and lncRNA DLEU2 in the two groups were analyzed. The logistic regression analysis model was used to analyze the prognostic predictive values of TCAB1 and lncRNA DLEU2 for PTC. t and χ² tests were used. Results　The relative expression level of lncRNA DLEU2 and the positive rate of TCAB1 in the cancer tissue were significantly higher than those in the adjacent tissue [(1.44±0.27) vs. (0.75±0.12), 72.78% (49/80) vs. 14.79% (22/80), ], with statistical differences (t=16.14; χ²=18.46; both P<0.05). There were statistical differences in the relative expression of lncRNA DLEU2 and TCAB1 positivity rate between the patients with different TNM stages and with and without lymph node metastases (all P<0.05). The results of Spearman correlation analysis showed that TCAB1 was positively associated with clinical stage and lymph node metastasis (r=0.428 and 0.353; both P<0.05), and lncRNA DLEU2 was positively associated with clinical stage and lymph node metastasis (r=0.430 and 0.401; both P<0.05). The relative expression level of lncRNA DLEU2 and the positive rate of TCAB1 in the poor prognosis group were significantly higher than those in the good prognosis group [(1.68±0.25) vs. (1.25±0.13) and 85.00% (17/20) vs. 53.33% (32/60)], with statistical differences (t=8.48 and χ²=6.34; both P<0.05). Positive expression of TCAB1 and increased relative expression of lncRNA DLEU2 were independent prognostic factors for PTC (OR=2.791, 95%CI 1.457-5.745; OR=2.146, 95%CI 1.525-6.795; both P<0.001). Conclusions　The expression levels of TCAB1 and lncRNA DLEU2 in the cancer tissue of PTC patients are increased, and are closely related to the occurrence and development of PTC. The expression levels of TCAB1 and lncRNA DLEU2 can be detected to predict the prognosis of patients with PTC.

Key words:

Thyroid cancer, Thyroid papillary carcinoma, Telomerase Cahalin protein 1, Long chain non-coding RNA, Pathological parameters, , Prognosis

戚新春李阳程卫.

甲状腺乳头状癌患者TCAB1、lncRNA DLEU2表达与临床病理参数及预后的相关性 [J]. 国际医药卫生导报, 2024, 30(19): 3302-3306.

Qi Xinchun, Li Yang, Cheng Wei.

Correlation of expression levels of TCAB1 and lncRNA DLEU2 with and clinical pathological parameters and prognosis in patients with papillary thyroid carcinoma [J]. International Medicine and Health Guidance News, 2024, 30(19): 3302-3306.

参考文献

[1] Zhang C, Gao X, Han Y,et al. Correlation between thyroid nodules and metabolic syndrome: a systematic review and meta-analysis[J]. Front Endocrinol (Lausanne),2021,12:730279.DOI: 10.3389/fendo.2021.730279.
[2] Brito JP, Gionfriddo MR, Al Nofal A,et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2014,99(4):1253-1263.DOI: 10.1210/jc.2013-2928.
[3] Alabousi M, Alabousi A, Adham S,et al. Diagnostic test accuracy of ultrasonography vs computed tomography for papillary thyroid cancer cervical lymph node metastasis: a systematic review and meta-analysis[J]. JAMA Otolaryngol Head Neck Surg, 2022,148(2):107-118.DOI: 10.1001/jamaoto.2021.3387.
[4] Jiang YF, Zhang HY, Ke J,et al. Overexpression of lncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers[J]. J Cell Mol Med,2019,23(8):4891-4899.DOI: 10.1111/jcmm.14486.
[5] 戢楠楠,邓文艺,刘瑞,等. TCAB1在宫颈鳞癌中的表达及其与患者术后临床病理特征及复发转移的关系[J]. 中国性科学,2023,32(5):100-104. DOI:10.3969/j.issn.1672-1993. 2023.05.026.
[6] 张波,徐景竹,吴琼. 2015年美国甲状腺学会«成人甲状腺结节与分化型甲状腺癌诊治指南»解读:超声部分[J]. 中国癌症杂志,2016(1):19-24. DOI:10.3969/j.issn.1007-3969. 2016.01.003.
[7] 章芹,丁文清.lncRNA DLEU2通过调控巨噬细胞M2极化对卵巢癌细胞转移的影响[J].中国优生与遗传杂志,2023,31(8):1581-1587.DOI:10.13404/j.cnki.cjbhh.2023.08.005.
[8] Yang J, Zhu X, Yuan P,et al. Efficacy of traditional Chinese medicine combined with chemotherapy in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized clinical trials[J]. Support Care Cancer, 2020,28(8):3571-3579.DOI: 10.1007/s00520-020-05433-w.
[9] Piccardo A, Fiz F, Bottoni G,et al. Does it work in childhood and adolescence? The predictive role of postoperative/preablative stimulated thyroglobulin levels in paediatric thyroid cancer. A systematic review of the literature[J]. Rev Endocr Metab Disord, 2024,25(1):53-63.DOI: 10.1007/s11154-023-09835-z.
[10] Chou R, Dana T, Haymart M,et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review[J]. Thyroid, 2022,32(4):351-367.DOI: 10.1089/thy.2021.0539.
[11] Petranović Ovčariček P, Verburg FA, Hoffmann M,et al. Higher thyroid hormone levels and cancer[J]. Eur J Nucl Med Mol Imaging, 2021,48(3):808-821.DOI: 10.1007/s00259-020-05018-z.
[12] 陈平,张鹤,李少军. miR-223-3p通过靶向TGFBR3促进LncRNA ADAMTS9-AS2表达上调抑制肺癌细胞的增殖和迁移作用[J]. 蚌埠医学院学报,2024,49(1):18-22. DOI:10.13898/j.cnki.issn.1000-2200.2024.01.004.
[13] Li Y, Rui X, Chen D,et al. LncRNA AWPPH as a prognostic predictor in human cancers in Chinese population: evidence from meta-analysis[J]. Biosci Rep, 2021,41(6):BSR20210012. DOI: 10.1042/BSR20210012.
[14] 鲁丹,张燚,胡安,等. TCAB1蛋白在喉鳞癌组织中的表达及与临床特征之间的关系[J]. 中国医药科学,2022,12(13):31-35. DOI:10.3969/j.issn.2095-0616.2022.13.009.
[15] 刘勇,晁方,秦刚,等. 喉鳞癌EBV感染危险因素及其对TCAB1、c-myc基因表达的影响[J]. 中华医院感染学杂志,2023,33(5):757-761. DOI:10.11816/cn.ni.2023-221083.
[16] Rastad H, Mozafary Bazargany MH, Samimisedeh P,et al. Clinicopathological and prognostic value of lncRNA TPT1-AS1 in cancer: a systematic review study and meta-analysis[J]. Pathol Res Pract, 2023 ,245:154403.DOI: 10.1016/j.prp.2023.154403.
[17] Seyed Hosseini E, Nikkhah A, Sotudeh A,et al. The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)[J]. Cancer Cell Int,2021,21(1):447.DOI: 10.1186/s12935-021-02125-1.
[18] 戢楠楠,邓文艺,陈秀秀,等. WRAP53与甲状腺乳头状癌患者临床病理特征及预后的关系[J]. 现代肿瘤医学,2024,32(1):60-64. DOI:10.3969/j.issn.1672-4992.2024.01.010.
[19] 王文玲,陈美华,刘旭丽,等. LncRNA DLEU2对宫颈癌细胞生物学行为、miR-21和Wnt/β-catenin信号通路的影响[J]. 广西医学,2023,45(24):2990-2997,3023. DOI:10.11675/j.issn.0253-4304.2023.24.11.